Diagnostic test developer Talis Biomedical Corp. and certain officers and directors were hit with a securities class action Friday in California Northern District Court over the company's Feb. 2021 IPO. The court action, filed by Glancy Prongay & Murray and the Law Offices of Frank R. Cruz, accuses the defendants of concealing likely delays in the launch of a COVID-19 test. The suit also names JPMorgan, BofA Securities, Piper Sandler and BTIG in their roles as underwriters of the IPO. Counsel have not yet appeared for the defendants. The case is 3:22-cv-00105, Modrak v. Talis Biomedical Corporation et al.